Detalles de la búsqueda
1.
CD34+ Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients.
Transfus Med Hemother
; 50(5): 428-437, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37899989
2.
Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study.
Transfusion
; 61(2): 516-525, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33245582
3.
CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study.
Transfusion
; 60(7): 1519-1528, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32333404
4.
A prospective comparison of pegfilgrastim and lipegfilgrastim combined with chemotherapy in the mobilization of CD34+ cells in NHL patients.
J Clin Apher
; 35(4): 255-263, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32311780
5.
Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era.
Br J Haematol
; 187(3): 364-371, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31267514
6.
Incidence of solid cancer in patients with follicular lymphoma.
Acta Oncol
; 58(11): 1564-1569, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31368395
7.
Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.
Carcinogenesis
; 38(8): 812-820, 2017 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28854563
8.
Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).
J Neurooncol
; 131(2): 293-300, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27752883
9.
Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.
Transfusion
; 55(10): 2358-68, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26018461
10.
Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.
Acta Oncol
; 54(6): 939-43, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25761092
11.
Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.
Transfusion
; 54(5): 1243-50, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24118008
12.
[Hodgkin's lymphoma]. / Hodgkinin lymfooma.
Duodecim
; 130(9): 913-20, 2014.
Artículo
en Fi
| MEDLINE | ID: mdl-24881143
13.
Loss of CD34+ Cells and Effect of the Number of Viable Cryopreserved CD34+ Cells in the Infused Blood Grafts on Hematologic Recovery, Progression-Free Survival and Overall Survival in NHL Patients After Autologous Stem Cell Transplantation.
Clin Lymphoma Myeloma Leuk
; 23(11): e428-e435, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37684185
14.
Blood Graft and Outcome After Autologous Stem Cell Transplantation in Patients With Primary Central Nervous System Lymphoma.
J Hematol
; 10(6): 246-254, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35059086
15.
Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study.
Leuk Lymphoma
; 61(9): 2082-2092, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32419549
16.
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis.
Blood Adv
; 4(9): 1906-1915, 2020 05 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32380536
17.
Low circulating levels of ProMMP-2 are associated with adverse prognosis in bladder cancer.
Tumour Biol
; 29(5): 279-86, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18802398
18.
Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.
Anticancer Res
; 28(3B): 1757-61, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18630455
19.
Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.
Sci Rep
; 8(1): 14814, 2018 10 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30287880
20.
Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
Clin Biochem
; 40(9-10): 640-4, 2007 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17374529